Chronic Daily Headache: A Rational Approach to a Challenging Problem

ABSTRACT

Chronic daily headache (CDH) is a significant public health problem with 3 to 5% of the population worldwide experiencing daily or near-daily headaches. Patients with CDH can be particularly challenging, and clinicians require a systematic approach to help guide investigations and management. The revised 2004 International Headache Society Classification Criteria introduces formalized criteria for several CDH disorders including chronic migraine and medication overuse headache as well as new daily persistent headache, hemicrania continua, hypnic headache, and SUNCT syndrome. Medication overuse is common in patients with CDH who present to physicians. Familiarity and comfort with drug-withdrawal and detoxification strategies is therefore essential. Patients with chronic migraine and chronic cluster experience significant disability and diminished quality of life. The ability to manage these patients effectively is a rewarding clinical experience.

KEYWORDS

Chronic daily headache - medication overuse headache - migraine - cluster headache

REFERENCES

• 1 Scher A I, Stewart W F, Liberman J. et al . Prevalence of frequent headache in a population sample.  Headache . 1998;  38 497-506
• 2 Castillo J, Munoz J, Guitera V. et al . Epidemiology of chronic daily headache in the general population.  Headache . 1999;  39 190-196
• 3 Wang S J, Fuh J L, Lu S R. et al . Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up.  Neurology . 2000;  54 314-319
• 4 Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache.  Curr Pain Headache Rep . 2001;  5 529-536
• 5 Lanteri-Minet M, Auray J P, El Hasnaoui A. Prevalence and description of chronic daily headache in the general population of France.  Pain . 2003;  102 143-149
• 6 Mathew N T. Chronic refractory headache.  Neurology . 1993;  43 (suppl 3) S26-S33
• 7 D'Amico D, Usai S, Grazzi L. et al . Quality of life and disability in primary chronic daily headache.  Neurol Sci . 2003;  24 S97-S100
• 8 Guitera V, Munoz P, Castillo J. et al . Quality of life in chronic daily headache. A study in general population.  Neurology . 2002;  58 1062-1065
• 9 Wang S J, Fuh J L, Lu S R. et al . Quality of life differs among headache diagnoses: analysis of SF-35 survey in 901 headache patients.  Pain . 2001;  89 285-292
• 10 Welch K M, Goadsby P J. Chronic daily headache: nosology and pathophysiology.  Curr Opin Neurol . 2002;  15 287-295
• 11 Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd ed.  Cephalalgia . 2004;  24(suppl 1) 1-160
• 12 Mokri B. Headaches caused by decreased intracranial pressure: diagnosis and management.  Curr Opin Neurol . 2003;  16 319-326
• 13 Dodick D W, Mosek A C, Campbell J K. The hypnic (“alarm clock”) headache syndrome.  Cephalalgia . 1998;  18 152-156
• 14 Dodick D. Hemicrania continua: diagnostic criteria and nosologic status.  Cephalalgia . 2001;  21 869-872
• 15 Peres M F, Silberstein S D, Nahmias S. et al . Hemicrania continua is not that rare.  Neurology . 2001;  57 948-951
• 16 Rozen T D. New daily persistent headache.  Curr Pain Headache Rep . 2003;  7 218-223
• 17 Tepper S J. Analgesic overuse is a cause of chronic daily headache.  Headache . 2002;  42 543-547
• 18 Dodick D W. Analgesic overuse is not a cause of chronic daily headache.  Headache . 2002;  42 547-554
• 19 Dowson A J, Dodick D W, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis (in press).  CNS Drugs 2003.
• 20 Silverman K, Evans S M, Strain E C. et al . Withdrawal syndrome after the double-blind cessation of caffeine consumption.  N Engl J Med . 1992;  327 1109-1114
• 21 Bahra A, Walsh M, Menon S. et al . Does chronic daily headache arise de novo in association with regular use of analgesics?.  Headache . 2003;  43 179-190
• 22 Young W B. Medication overuse headache.  Curr Treat Options Neurol . 2001;  3 181-188
• 23 Zed P J, Loewen P S, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches.  Ann Pharmacother . 1999;  33 61-72
• 24 Boes C, Jones J M, Dodick S W. Self-administered subcutaneous dihydroergotamine in the outpatient treatment of chronic daily headache with medication overuse.  Headache . 2000;  40 402
• 25 Mathew N T, Stubits E, Nigam M P. Transformation of episodic migraine into daily headache: analysis of factors.  Headache . 1982;  22 66-68
• 26 Silberstein S D, Lipton R B, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised HIS criteria.  Neurology . 1996;  47 871-875
• 27 Matthew N T. Transformed migraine, analgesic rebound, and other chronic daily headaches.  Neurol Clin . 1997;  15 167-186
• 28 Scher A., Lipton R B, Stewart W F. Risk factors for chronic daily headache.  Curr Pain Headache Rep . 2002;  6 486-491
• 29 Scher A I, Lipton R B, Stewart W F. Habitual snoring as a risk factor for chronic daily headache.  Neurology . 2003;  60 1366-1368
• 30 Bahra A, Matharu M S, Buchel C, Frackowiak R S, Goadsby P J. Brainstem activation specific to migraine headache.  Lancet . 2001;  357 1016-1017
• 31 Tracey I, Ploghaus A, Gati J S. et al . Imaging attentional modulation of pain in the periaqueductal gray in humans.  J Neurosci . 2002;  22 2748-2752
• 32 Silberstein S D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology . 2000;  55 754-762
• 33 Brandes J L, Jacobs D, Neto W. et al . Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, parallel study (MIGR-002).  Neurology . 2003;  60 A238
• 34 Mathew N T, Schmitt J, Jacobs D. et al . Topiramate in migraine prevention (MIGR-001): effect on migraine frequency.  Neurology . 2003;  60 A336
• 35 Ondo W G, Vuong K D, Derman H S. Botulinum toxin A (BOTOX^®) for chronic daily headache: a randomized placebo-controlled, parallel design study (in press).  Cephalalgia 2003.
• 36 Freitag F G, Collins S D, Carlson H A. et al . Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.  Neurology . 2002;  58 1652-1659
• 37 Storer R J, Goadsby P J. Topiramate inhibits trigeminovascular traffic in the cat: possible locus of action in the prevention of migraine.  Neurology . 2003;  60(S1) A238-A239
• 38 Cui M, Aoki K R. Botulinum toxin type A (BONT/A) reduces inflammatory pain in the rat formalin model.  Cephalalgia . 2000;  20 414
• 39 Cui M, Li S, You S, Khanijou S, Aoki K R. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing. International Conference 2002 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hanover, Germany, June 8-11, 2002.  Naunyn Schmiedebergs Arch Pharmacol . 2002;  365 (suppl 2) R17
• 40 Rosales R L, Arimura K, Ikenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection.  Muscle Nerve . 1996;  19 488-496
• 41 Silberstein S D. Review of botulinum toxin type A and its clinical applications in migraine headache.  Expert Opin Pharmacother . 2001;  2 1649-1654
• 42 Dodick D W, Capobianco D J. Treatment and management of cluster headache.  Curr Pain Headache Rep . 2001;  5 83-91
• 43 Dodick D, Rozen T, Goadsby P, Silberstein S. Cluster headache.  Cephalalgia . 2000;  20 787-803
• 44 May A, Leone M. Update on cluster headache.  Curr Opin Neurol . 2003;  16 333-340
• 45 Leone M, Franzini A, D'Amico A. et al . Preliminary results and follow up of stereotactic electrode implant in posterior hypothalamic gray matter to relieve intractable chronic cluster headache.  Neurology . 2002;  58 89-90